Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice

Rashdan, Sawsan; Gerber, David E.

doi:10.21037/tlcr.2018.09.15

Cited by 18 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Experiences from real-world data have been published, suggesting that the efficacy and safety profiles of immunotherapy are consistent with those reported in clinical trials [ 10 , 12 ]. These studies are useful in providing further evidence of the benefits of treatments in a wider range of patients, including those underrepresented in clinical trials [ 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 57%

“…Patients participating in RCTs are generally younger and healthier than patients in the general population, are more likely to tolerate treatment, derive clinical benefits, and have a better performance status [ 10 ]. The strict eligibility criteria do not allow RCTs to fully represent the treatment effects in the patients that will ultimately use the drugs.…”

Section: Discussionmentioning

confidence: 99%

“…In real-world settings, patients are more heterogeneous. Generally, studies in clinical practice evaluate a meaningful proportion of patients not enrolled in clinical trials, including 30 to 50% of patients with advanced age, ECOG performance status ≥2, multiple co-morbidities, and/or brain metastases [ 10 ]. This way, real-world data may be helpful to evaluate the reproducibility of outcomes of novel treatments, and to identify new information on efficacy that can be used in treatment decision-making [ 10 , 11 ].…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, cancer patients enrolled in randomized clinical trials (RCT) meet strict eligibility criteria allowing for the treatment of patients that do not reflect the more heterogeneous population of oncologic patients. Being nonselective, the reported experience of immunotherapy described in real-world studies may provide complementary data to clinical trial findings [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis

Ceppi

Bruzzone

Taveggia³

et al. 2021

Cancers

View full text Add to dashboard Cite

Immunotherapy based on anti PD-1/PD-L1 inhibitors is the new standard of advanced non-small cell lung cancers. Pembrolizumab, nivolumab and atezolizumab are used in clinical practice. The strict eligibility criteria of clinical trials do not allow researchers to fully represent treatment effects in the patients that will ultimately use these drugs. We performed a systematic review and a meta-analysis to evaluate the effectiveness and safety of these drugs, and more generally of ICIs, as second-line therapy in NSCLC patients in real world practice. MEDLINE, PubMed, Scopus and Web of Science were searched to include original studies published between January 2015 and April 2020. A total of 32 studies was included in the meta-analysis. The overall radiological response rate (ORR), disease control rate (DCR), median progression-free survival (PFS) and overall survival (OS) were 21%, 52%, 3.35 months and 9.98 months, respectively. The results did not change when analysis was adjusted for Eastern Cooperative Oncology Group performance status (ECOG PS) and age. A unitary increase in the percent of patients with liver and CNS metastases reduced the occurrence of DCR by 7% (p < 0.001) and the median PFS by 2% (p = 0.010), respectively. The meta-analysis showed that the efficacy and safety of immunotherapy in everyday practice is comparable to that in clinical trials.

show abstract

Section: Introductionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis

Ceppi

Bruzzone

Taveggia³

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…16,17,18 Terdapat sedikit data keamanan dan efektifitas agen anti-PD-1 / anti-PD-L1 pada pasien dengan ECOG (Eastern Cooperative Oncology Group ) PS yang buruk, lansia, pasien dengan metastasis otak asimptomatik yang tidak diobati, pasien dengan penyakit autoimun, dan pasien dengan penggunaan steroid kronis. 19…”

Section: Efek Samping Pemberian Immunoterapi Pada Pasien Kanker Paruunclassified

Peranan Immunoterapi Pada Kanker Paru

Andayani¹,

Julisafrida²

2020

JKS

View full text Add to dashboard Cite

Abstrak. Kanker paru masih menjadi masalah kesehatan secara menyeluruh, baik di dunia maupun di Indonesia, khususnya di Aceh. Saat ini kanker paru masih menjadi penyebab kematian tertinggi di dunia. Berbagai peneletian tentang tatalaksana kanker paru telah dikembangkan, perkembangan terapi kanker paru saat ini berupa immunoterapi yang menargetkan reseptor penghambat sel T, seperti program sel death (PD-1) , terapi checkpoint blockade, immunoterapi baru berdasarkan neoantigen selektif dengan tujuan pengobatan mampu mendorong sel yang di transformasikan.Immunoterapi adalah salah satu metode pengobatan berbagai jenis tumor dengan efek samping yang dapat di atasi. Tujuan imunoterapi kanker adalah memberikan efektor antitumor (antibodi dan sel T ) terhadap pasien. Perkembangan ilmu pengetahuan tentang tatalaksana kanker berkembang sangat pesat, baik yang bersifat invasif maupun yang non invasif hingga penatalaksaan nano molekul. Tujuan pengobatan beruapa peningkatan kualitas hidup dan peningkatan survival rate.Kata Kunci : kanker paru, immunoterapi, PD-1, PD-L1, checkpoint blockadeAbstract. Lung cancer is still a comprehensive health problem, both in the world and in Indonesia, especially in Aceh. Currently lung cancer is still the highest cause of death in the world. Various studies on the management of lung cancer have been developed, the development of lung cancer therapy currently in the form of immunotherapy that targets T cell receptor inhibitors, such as the cell death program (PD-1), checkpoint blockade therapy, new immunotherapy based on selective neoantigens with the aim of treatment being able to encourage cells that transformed.Immunotherapy is one method of treating various types of tumors with side effects that can be overcome. The aim of cancer immunotherapy is to provide antitumor effectors (antibodies and T cells) to patients. The development of science about cancer management is developing very rapidly, both invasive and non-invasive to the management of nano molecules. Treatment goals include improving the quality of life and increasing survival rates.Keyword: lung cancer, immunotherapy, PD-1, PD-L1, checkpoint blockade

show abstract

Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives

et al. 2022

View full text Add to dashboard Cite

Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice

Cited by 18 publications

References 36 publications

Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis

Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis

Peranan Immunoterapi Pada Kanker Paru

Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives

Contact Info

Product

Resources

About